MetFlex: safety and tolerability of trimetazidine in ALS
Duration:
January 2020–December 2023
Project Summary
MetFlex is an investigator initiated and conducted, multicentre, international, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).
